Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
FDA lifts partial clinical hold on Zentalis Pharmaceuticals' azenosertib studies, allowing resumption of enrollment in ongoing clinical trials without changes to the development plan. Zentalis remains confident in azenosertib's therapeutic potential for gynecologic malignancies and plans to present monotherapy data later this year.
Reference News
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
FDA lifts partial clinical hold on Zentalis Pharmaceuticals' azenosertib studies, allowing resumption of enrollment in ongoing clinical trials without changes to the development plan. Zentalis remains confident in azenosertib's therapeutic potential for gynecologic malignancies and plans to present monotherapy data later this year.